WHAT SHOULD THE INTERNIST KNOW ABOUT TARGETED THERAPY IN SOLID TUMORS? (ONCONEPHROLOGY)

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

EL RASSY ELIE; KARAK FADI EL; RIZKALLAH JAMALE; CHELALA DANIA

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Iranian Journal of Kidney Diseases Year:2016 | Volume:10 | Issue:4 Page(s): 169-175

Download Full-Text

View:

415

Download:

134

Cites:

Information Journal Paper

Title

WHAT SHOULD THE INTERNIST KNOW ABOUT TARGETED THERAPY IN SOLID TUMORS? (ONCONEPHROLOGY)

Author(s)

EL RASSY ELIE | KARAK FADI EL | RIZKALLAH JAMALE | CHELALA DANIA | Issue Writer Certificate

Keywords

ONCOLOGY

NEPHROLOGY

TARGETED THERAPIES

KIDNEY DISEASE VASCULAR ENDOTHELIAL GROWTH FACTOR

ENDOTHELIAL GROWTH FACTOR

Abstract

Advances in medical ONCOLOGY has led cancer patients to live longer.Moreover, the field of molecular ONCOLOGY is rapidly evolving, new therapies emerge, and drugs are approved quickly. This has led nephrologists to encounter new and partially unrecognized treatments of the targeted therapy agents with kidney adverse effects. These agents fall mainly into 2 categories affecting the vascular ENDOTHELIAL GROWTH FACTOR and ENDOTHELIAL GROWTH FACTOR pathways. This review covers the incidence of kidney disease induced by these agents, pathophysiologic mechanisms, and clinical presentation, and is the first to recommend an adequate management for each pathophysiology.

Cites

No record.

References

No record.

Cite

APA: Copy

EL RASSY, ELIE, KARAK, FADI EL, RIZKALLAH, JAMALE, & CHELALA, DANIA. (2016). WHAT SHOULD THE INTERNIST KNOW ABOUT TARGETED THERAPY IN SOLID TUMORS? (ONCONEPHROLOGY). IRANIAN JOURNAL OF KIDNEY DISEASES (IJKD), 10(4), 169-175. SID. https://sid.ir/paper/309503/en

Vancouver: Copy

EL RASSY ELIE, KARAK FADI EL, RIZKALLAH JAMALE, CHELALA DANIA. WHAT SHOULD THE INTERNIST KNOW ABOUT TARGETED THERAPY IN SOLID TUMORS? (ONCONEPHROLOGY). IRANIAN JOURNAL OF KIDNEY DISEASES (IJKD)[Internet]. 2016;10(4):169-175. Available from: https://sid.ir/paper/309503/en

IEEE: Copy

ELIE EL RASSY, FADI EL KARAK, JAMALE RIZKALLAH, and DANIA CHELALA, “WHAT SHOULD THE INTERNIST KNOW ABOUT TARGETED THERAPY IN SOLID TUMORS? (ONCONEPHROLOGY),” IRANIAN JOURNAL OF KIDNEY DISEASES (IJKD), vol. 10, no. 4, pp. 169–175, 2016, [Online]. Available: https://sid.ir/paper/309503/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops